Also known as Lys-Glu-Asp-Pro · KEDP tetrapeptide
Synthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator — the defined-sequence successor to older prostate extracts.
Research refreshed
Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) in the Khavinson short-peptide bioregulator series, directed at prostate tissue. It was conceived as the defined single-sequence successor to older bovine prostate extracts (such as Prostatilen), studied for prostate inflammation and age-related remodeling.
Prostamax (Lys-Glu-Asp-Pro) is the prostate-directed member of the defined short-peptide bioregulator family. Where the earlier generation used bovine prostate extracts (Prostatilen, Vitaprost), Prostamax is the synthetic, single-sequence peptide meant to reproduce that tissue-selective effect in a defined molecule.
Reported research — largely Khavinson-school animal and cell-culture work — describes reduced prostate inflammation and slowed pathological remodeling in rat prostatitis models. There are no Western randomized trials of the synthetic peptide and no independent replication outside the originating institute, and it is not FDA-approved.
Proposed gene-regulatory modulation of prostate gene expression.
Behind every vial of Prostamax is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Prostamax, specifically, is brought into being.
On paper, Prostamax is C20H33N5O9 — about 487.5 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Prostamax means roughly 4 coupling cycles on the synthesizer — one protected residue added at a time, which is also 4 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Prostamax plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Prostamax proves itself: identity confirmed by mass spectrometry against its ~487.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Prostamax — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Prostamax (Lys-Glu-Asp-Pro) is a tetrapeptide made by routine solid-phase synthesis; the proline residue is a standard building block, so assembly is straightforward and quality hinges on deletion-sequence and counterion control.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Prostamax is a synthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator in the Khavinson short-peptide series.
It is the defined single-sequence synthetic successor to bovine prostate extracts like Prostatilen and Vitaprost, meant to reproduce their tissue-selective effect in a defined molecule.
It is concentrated in one research tradition and largely preclinical, with no independent replication. This page is a research and educational reference.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
ViewThe natural pineal peptide bioregulator — the animal-derived counterpart to synthetic Epitalon, marketed for aging and telomere support.
ViewThymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.